214 related articles for article (PubMed ID: 33239043)
1. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
2. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
[TBL] [Abstract][Full Text] [Related]
3. Histone H3.3K27M Represses
Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
[TBL] [Abstract][Full Text] [Related]
4. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
[TBL] [Abstract][Full Text] [Related]
6. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
7. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
8. H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells.
Leszczynska KB; Freitas-Huhtamäki A; Jayaprakash C; Dzwigonska M; Vitorino FNL; Horth C; Wojnicki K; Gielniewski B; Szadkowska P; Kaza B; Nazarian J; Ciolkowski MK; Trubicka J; Grajkowska W; Garcia BA; Majewski J; Kaminska B; Mieczkowski J
Cell Rep; 2024 Feb; 43(2):113707. PubMed ID: 38306270
[TBL] [Abstract][Full Text] [Related]
9. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
10. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
[TBL] [Abstract][Full Text] [Related]
11. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
[TBL] [Abstract][Full Text] [Related]
12. Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma.
Parsels LA; Wahl DR; Koschmann C; Morgan MA; Zhang Q
Neoplasia; 2023 Mar; 37():100881. PubMed ID: 36724689
[TBL] [Abstract][Full Text] [Related]
13. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
15. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.
Fang D; Gan H; Cheng L; Lee JH; Zhou H; Sarkaria JN; Daniels DJ; Zhang Z
Elife; 2018 Jun; 7():. PubMed ID: 29932419
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]